Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESHAOx for Refractory or Relapsed Hodgkin's Lymphoma
NCT01300156Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2011
- Primary completion
- Jun 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin in Hodgkin lymphoma (HL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01300156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01300156.